Binghe Xu

Also affiliated with Chinese Academy of Medical Sciences & Peking Union Medical College

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)”.

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)

European Journal of Cancer(2021)10.1016/j.ejca.2021.01.053

N/A

0.685DataRank · unranked

28 citations

Eileen Holmes, Christian Jackisch, Evandro de Azambuja, Frances Boyle, David W. Hillman +37 more

OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

European Journal of Cancer(2023)10.1016/j.ejca.2023.01.031

N/A

0DataRank · unranked

113 citations

Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda +8 more

First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors

The Oncologist(2024)10.1093/oncolo/oyad338

N/A

0DataRank · unranked

27 citations

Binghe Xu, Ecaterina E. Dumbrava, Siqing Fu, Daniel D. Karp, Funda Meric‐Bernstam +20 more